Business Description
Intensity Therapeutics is a Connecticut-based biotech company founded in 2012 that develops cancer treatments targeting both localized tumors and cancer that has spread throughout the body. Its primary drug, INT230-6, is currently being tested in late-stage clinical trials for soft tissue sarcoma and triple negative breast cancer.
